Abstract C46: The pharmacokinetics and pharmacodynamics study of honokiol in Sprague-Dawley rats and colorectal tumor-bearing mice

Honokiol, a small-molecule pharmacological bioactive constituent of the bark of Magnolia plants, has shown anti-tumor effect in a variety of human cancer xenograft models through the induction of apoptosis. Additionally, honokiol could enhance the cytotoxicity in combination of oxaliplatin in colon cancer cells. To investigate the anti-tumor effect and the pharmacokinetics (PK) of honokiol, honokiol was tested for anti-tumor activity in a colorectal cancer xenograft mice model and oral-bioavailability of honokiol was assayed in Sprague-Dawley rats. The pharmacokinetic results of 5.0 mg/kg honokiol after intravenous injection showed that the elimination half time was about 0.79 ± 0.03 hours, the Cmax was about 752.67 ± 58.36 ng/mL, and the mean residence time (MRT) was about 0.85 ± 0.05 hours. In vivo study for testing anti-cancer activity of honokiol is underwent and expected that honokiol would inhibit the tumor growth in colorectal tumor-bearing mice. In conclusion, honokiol may be developed be as therapeutic agent for cancer treatment in combination with PK and pharmacodynamics (PD) data. Citation Format: Yung-Jen Tsai, Pei-Yi Tsai, Le-Mei Hung, Mei-Yin Su, Min-Hui Lin, Lung-Yu Kuan, Yih-Chiao Tsai, Hui-Ling Chen, Jia-Ming Chang. The pharmacokinetics and pharmacodynamics study of honokiol in Sprague-Dawley rats and colorectal tumor-bearing mice. [abstract]. In: Proceedings of the Third AACR International Conference on Frontiers in Basic Cancer Research; Sep 18-22, 2013; National Harbor, MD. Philadelphia (PA): AACR; Cancer Res 2013;73(19 Suppl):Abstract nr C46.